Accentia Biopharmaceuticals Inc
Tampa
About Accentia Biopharmaceuticals Inc
Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products, such as whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $775.0K
- Funding stage: IPO
- Last round: Series Unknown (Jun 2013)
- Ticker: nasdaq:ABPI
- Website: accentia.net
- Phone: 813-864-2554
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/accentia-biopharmaceuticals-inc-3237204 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.